Itracon (Itraconazole)

Itraconazole is a systemic azole antifungal used to treat infections caused by susceptible fungi.

• Dermatophytosis: eradicates skin‑surface fungal infections, leading to resolution of lesions and itching.
• Onychomycosis: clears fungal nail infection, promoting regrowth of healthy nail tissue.
• Blastomycosis: treats systemic blastomyces infection, reducing pulmonary and disseminated disease manifestations.
• Histoplasmosis: combats histoplasma capsulatum infection, improving respiratory symptoms and preventing spread.
• Aspergillosis: controls invasive aspergillus disease, especially in immunocompromised patients.
• Candidiasis: resolves mucosal and systemic candidal infections, decreasing fungal burden.

• Itraconazole exerts its antifungal activity by binding to the fungal cytochrome P450 enzyme lanosterol 14α‑demethylase. This inhibition blocks the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. Depletion of ergosterol and accumulation of toxic sterol intermediates compromise membrane integrity, leading to inhibited growth and eventual death of susceptible fungal cells. The effect is concentration‑dependent and persists while therapeutic plasma levels are maintained.

Itraconazole may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Nausea: mild gastrointestinal upset, often transient.
• Headache: transient cranial discomfort, usually low‑grade.
• Abdominal pain: intermittent stomach cramps or discomfort.
• Diarrhea: loose stools that may be watery.
• Elevated liver enzymes: mild increase in hepatic transaminases.
• Rash: mild skin irritation or erythema.

Serious or Rare Side Effects

• Hepatotoxicity: severe liver injury, jaundice or hepatic failure.
• Congestive heart failure: worsening of pre‑existing cardiac function, edema.
• Severe hypersensitivity: anaphylactic reactions or Stevens‑Johnson syndrome.
• Visual disturbances: blurred vision, photopsia or color perception changes.
• QT prolongation: cardiac rhythm abnormalities that may lead to arrhythmia.
• Severe skin reactions: toxic epidermal necrolysis or extensive blistering.

When prescribing itraconazole, clinicians should consider several precautionary measures to ensure safe use.

• Liver function: assess baseline hepatic enzymes and monitor periodically.
• Cardiac status: avoid in patients with existing heart failure or significant ventricular dysfunction.
• Drug interactions: review concomitant medications that affect CYP3A4 metabolism.
• Pregnancy and lactation: use only if potential benefit outweighs risk; data limited.
• Gastrointestinal absorption: advise patients to take with food or acidic beverage to improve bioavailability.
• Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and light.

Itraconazole is metabolized by and can affect several cytochrome P450 enzymes, leading to notable drug interactions.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): markedly reduce itraconazole exposure.
• Certain statins (e.g., simvastatin, lovastatin): increased risk of myopathy and rhabdomyolysis.
• QT‑prolonging agents (e.g., quinidine, sotalol): additive risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase itraconazole levels, monitor for toxicity.
• Anticoagulants (e.g., warfarin): potential alteration of INR, require closer monitoring.
• Oral hypoglycemics (e.g., sulfonylureas): possible enhanced hypoglycemic effect.